<p>, /PRNewswire/ -- 2026 年美国临床肿瘤学会（ASCO）年会于 5 月 29 日至 6 月 2 日在芝加哥举行（当地时间）。作为全球领先的肿瘤学会议之一，ASCO 年会是展示癌症研究和临床发展的重要平台。今年，恒瑞医药展示了超过 90 项涵盖多种肿瘤类型和治疗方式的研究。</p>
<p>根据统计，今年有 94 个中国研究项目被选为 ASCO 的口头报告，包括 12 个最新突破摘要，标志着连续第三年增长。在 2026 年 ASCO 年会上，恒瑞医药展示了 91 项被接受的研究和 11 个口头报告，涉及创新疗法，突显了公司肿瘤学管线的广度和对创新药物开发的持续投资。</p>
<p>作为中国领先的创新制药公司，恒瑞持续专注于肿瘤研究和药物开发。连续 16 年，恒瑞在 ASCO 年会上分享其肿瘤学产品组合的数据。今年，公司研究项目涵盖多个关键领域，包括胃肠癌、乳腺癌、肺癌、泌尿系统癌症、妇科癌症和支持性癌症护理，涉及 11 种已批准药物、10 种管线候选药物和一种二类新药（NMPA 分类）。这些项目得到了超过 10 个技术平台的支持，涵盖小分子、抗体药物偶联物（ADCs）、双特异性和多特异性抗体以及降解剂。这些基于平台的研发能力支持了涵盖多种治疗方法的广泛肿瘤学管线。</p>
<p><strong>乳腺癌：新数据支持多种新兴治疗策略</strong></p>
<p>对于三阴性乳腺癌，由河南省肿瘤医院刘振振教授领导的 HELEN-Trio 011 研究显示，使用卡瑞利珠单抗联合化疗的术前治疗的病理完全缓解率（pCR）达到 57.5%，显著优于单独化疗的 45.4% pCR。在 HER2 阳性早期乳腺癌的术前治疗领域，HELEN HER-013 研究首次证明，纳米颗粒白蛋白结合的紫杉醇、曲妥珠单抗和酪氨酸激酶抑制剂吡咯替尼（nab-PHPy）的化疗减量方案在疗效上不劣于标准的 TCHP，为无法耐受严重血液毒性的患者提供了新的治疗选择。</p>
<p><strong>胃肠癌：抗体药物偶联物与免疫治疗联合治疗展现前景</strong></p>
<p>在结直肠癌领域，由中国药科大学附属上海高博肿瘤医院的李进教授和浙江大学医学院附属第二医院的袁颖教授领导的 HORIZON-CRC01 研究表明，新一代抗 HER2 抗体药物偶联物曲妥珠单抗瑞泽坦在治疗经过标准二线治疗后进展的 HER2 阳性、RAS 和 RAF 野生型晚期结直肠癌患者时，获得了 5.5 个月的中位无进展生存期（PFS），而常规化疗为 2.8 个月，提示为经过标准治疗后病情进展的患者提供了潜在的新治疗选择。在肝癌领域，由复旦大学附属中山医院的贾凡院士和慈溪市先进研究所的秦树奎教授共同领导的 CARES-336 研究首次证明，“卡瑞利珠单抗 + 阿帕替尼” 方案联合经动脉化疗栓塞（TACE）显著延长了中位 PFS（根据 BIRC 的 mRECIST，11.1 个月对比 8.3 个月），支持该联合方案在不可切除肝细胞癌（uHCC）患者中的潜在应用。</p>
<p><strong>泌尿系统癌症：前列腺癌和膀胱癌的双重突破</strong></p>
<p>由复旦大学上海癌症中心的叶丁伟教授领导的 FUZUPRO 研究表明，针对转移性去势抵抗性前列腺癌（mCRPC）的首选治疗中，氟唑帕利联合阿比特龙和泼尼松的治疗中位放射学 PFS 为 24.8 个月，而标准方案为 19.9 个月。另一项研究表明，抗 Nectin-4 抗体药物偶联物 SHR-A2102 联合阿德贝利单抗在肌肉侵袭性膀胱癌的围手术期治疗中，获得了 48.1% 的 pCR 和 59.3% 的病理降期率，包括肾功能不全患者。</p>
<p><strong>支持性癌症护理：新抗恶心药物的额外证据</strong></p>
<p>由中山大学肿瘤中心的张莉教授和李玉红教授领导的 III 期 PROTECT 研究表明，恒瑞自主研发的新型超长效抗恶心药物 Fosrolapitant 和盐酸帕洛诺司琼注射液在预防中度致吐化疗引起的恶心和呕吐的急性、延迟和整体阶段中，获得了显著高于标准方案的完全应答率。这些发现为其在支持性癌症护理中的应用提供了越来越多的临床证据。</p>
<p><strong>恒瑞医药</strong> 目前在中国市场上销售 16 种已批准的肿瘤药物，并在其研究组合中推进近 60 个肿瘤候选药物。公司在全球范围内开展超过 150 项临床试验，涵盖其关键的肿瘤开发项目。</p>
<p>恒瑞在 ASCO 年会上的不断扩展反映了其肿瘤管线和更广泛的临床开发工作的持续进展。今年公司的研究报告涵盖多种肿瘤类型和治疗方式，突显了其肿瘤产品组合中的已批准药物和研究候选药物。</p>
<p>随着全球肿瘤研究的不断发展，恒瑞医药始终专注于通过持续的研发投资，将科学创新转化为患者潜在的临床益处。</p>
<p>来源：恒瑞医药</p>
<p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNjAxJk5ld3NJdGVtSWQ9Q043MjIyNCZUcmFuc21pc3Npb25fSWQ9MjAyNjA2MDEwMTUxUFJfTkVXU19VU1BSX19fX19DTjcyMjI0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNjAxJk5ld3NJdGVtSWQ9Q043MjIyNCZUcmFuc21pc3Npb25fSWQ9MjAyNjA2MDEwMTUxUFJfTkVXU19VU1BSX19fX19DTjcyMjI0"/></p>

恒瑞医药

平安中证医疗创新ETF

博时恒生医疗保健(QDII-ETF)

博时恒生港股通创新药精选ETF

<p>恒瑞医药在 2026 年美国临床肿瘤学会（ASCO）年会上展示了超过 90 项肿瘤学研究，突显了在多种肿瘤类型上的进展。关键发现包括在乳腺癌中使用 camrelizumab 联合治疗改善了病理完全缓解率，在结直肠癌和肝癌中使用抗体药物偶联物（ADCs）和免疫疗法增强了无进展生存期，以及在前列腺癌和膀胱癌治疗方面的突破。该公司还展示了一种新型抗恶心药物的数据，进一步巩固了其广泛的肿瘤学产品线和研发能力</p>

<p>, /PRNewswire/ -- The 2026 American Society of Clinical Oncology (ASCO) Annual Meeting was held in Chicago from May 29 to June 2 (local time). As one of the world's leading oncology conferences, the ASCO Annual Meeting serves as a key venue for presenting advances in cancer research and clinical development. This year, Hengrui Pharma presented more than 90 studies spanning multiple tumor types and therapeutic modalities.</p>
<div class="lb-trans"><p>, /PRNewswire/ -- 2026 年美国临床肿瘤学会（ASCO）年会于 5 月 29 日至 6 月 2 日在芝加哥举行（当地时间）。作为全球领先的肿瘤学会议之一，ASCO 年会是展示癌症研究和临床发展的重要平台。今年，恒瑞医药展示了超过 90 项涵盖多种肿瘤类型和治疗方式的研究。</p>
</div><p>According to statistics, 94 Chinese research projects were selected for oral presentations at ASCO this year, including 12 late-breaking abstracts, marking the third consecutive year of growth. At 2026 ASCO Annual Meeting, Hengrui Pharma presented 91 accepted studies and 11 oral presentations featuring innovative therapies, underscoring the breadth of the company's oncology pipeline and ongoing investment in innovative drug development.</p>
<div class="lb-trans"><p>根据统计，今年有 94 个中国研究项目被选为 ASCO 的口头报告，包括 12 个最新突破摘要，标志着连续第三年增长。在 2026 年 ASCO 年会上，恒瑞医药展示了 91 项被接受的研究和 11 个口头报告，涉及创新疗法，突显了公司肿瘤学管线的广度和对创新药物开发的持续投资。</p>
</div><p>As a leading innovative pharmaceutical company in China, Hengrui continues to focus on oncology research and drug development. For 16 consecutive years, Hengrui has shared data from its oncology portfolio at the ASCO Annual Meeting. This year, the company's research program encompasses multiple key areas, including gastrointestinal cancers, breast cancer, lung cancer, urological cancers, gynecological cancers, and supportive cancer care, covering 11 approved medicines, 10 pipeline candidates, and one Class 2 new drug (NMPA classification). These programs are supported by more than 10 technology platforms covering small molecules, ADCs, bispecific and multispecific antibodies, and degraders. Together, these platform-based R&amp;D capabilities support a broad oncology pipeline encompassing multiple therapeutic approaches across different tumor types.</p>
<div class="lb-trans"><p>作为中国领先的创新制药公司，恒瑞持续专注于肿瘤研究和药物开发。连续 16 年，恒瑞在 ASCO 年会上分享其肿瘤学产品组合的数据。今年，公司研究项目涵盖多个关键领域，包括胃肠癌、乳腺癌、肺癌、泌尿系统癌症、妇科癌症和支持性癌症护理，涉及 11 种已批准药物、10 种管线候选药物和一种二类新药（NMPA 分类）。这些项目得到了超过 10 个技术平台的支持，涵盖小分子、抗体药物偶联物（ADCs）、双特异性和多特异性抗体以及降解剂。这些基于平台的研发能力支持了涵盖多种治疗方法的广泛肿瘤学管线。</p>
</div><p><strong>Breast Cancer: New Data Support Multiple Emerging Treatment Strategies</strong></p>
<div class="lb-trans"><p><strong>乳腺癌：新数据支持多种新兴治疗策略</strong></p>
</div><p>For triple-negative breast cancer, the HELEN-Trio 011 study led by Professor Zhenzhen Liu of Henan Cancer Hospital showed that the pathological complete response (pCR) rate for neoadjuvant therapy with camrelizumab combined with chemotherapy reached 57.5%, significantly outperforming the pCR of 45.4% observed with chemotherapy alone. In the field of neoadjuvant therapy for HER2-positive early breast cancer, the HELEN HER-013 study was the first to demonstrate that the chemotherapy-de-escalated regimen of nanoparticle albumin-bound paclitaxel, trastuzumab, and the tyrosine kinase inhibitor pyrotinib (nab-PHPy) is noninferior to standard TCHP, offering a new treatment option for patients who cannot tolerate severe hematologic toxicity.</p>
<div class="lb-trans"><p>对于三阴性乳腺癌，由河南省肿瘤医院刘振振教授领导的 HELEN-Trio 011 研究显示，使用卡瑞利珠单抗联合化疗的术前治疗的病理完全缓解率（pCR）达到 57.5%，显著优于单独化疗的 45.4% pCR。在 HER2 阳性早期乳腺癌的术前治疗领域，HELEN HER-013 研究首次证明，纳米颗粒白蛋白结合的紫杉醇、曲妥珠单抗和酪氨酸激酶抑制剂吡咯替尼（nab-PHPy）的化疗减量方案在疗效上不劣于标准的 TCHP，为无法耐受严重血液毒性的患者提供了新的治疗选择。</p>
</div><p><strong>Gastrointestinal Cancers: ADC and Immunotherapy Combination Treatments Show Promise</strong></p>
<div class="lb-trans"><p><strong>胃肠癌：抗体药物偶联物与免疫治疗联合治疗展现前景</strong></p>
</div><p>In the field of colorectal cancer, the HORIZON-CRC01 study led by Professor Jin Li of Shanghai GoBroad Cancer Hospital Affiliated to China Pharmaceutical University and Professor Ying Yuan of The Second Affiliated Hospital of Zhejiang University School of Medicine demonstrated that the new-generation anti-HER2 ADC, trastuzumab rezetecan, when used to treat patients with HER2-positive, RAS and RAF wild-type advanced colorectal cancer who have progressed after standard second-line therapy, achieved a median progression-free survival (PFS) of 5.5 months, compared to 2.8 months with conventional chemotherapy, suggesting a potential new treatment option for patients whose disease has progressed following standard therapies. In the field of liver cancer, the CARES-336 study, co-led by Academician Jia Fan from Zhongshan Hospital Affiliated to Fudan University and Professor Shukui Qin from Tsientang Institute for Advanced Study, has for the first time demonstrated that the &#34;Camrelizumab + Apatinib&#34; regimen combined with transarterial chemoembolization (TACE) significantly prolongs median PFS compared to TACE alone (by BIRC per mRECIST, 11.1 months vs. 8.3 months), supporting the potential use of this combination approach in patients with unresectable hepatocellular carcinoma (uHCC).</p>
<div class="lb-trans"><p>在结直肠癌领域，由中国药科大学附属上海高博肿瘤医院的李进教授和浙江大学医学院附属第二医院的袁颖教授领导的 HORIZON-CRC01 研究表明，新一代抗 HER2 抗体药物偶联物曲妥珠单抗瑞泽坦在治疗经过标准二线治疗后进展的 HER2 阳性、RAS 和 RAF 野生型晚期结直肠癌患者时，获得了 5.5 个月的中位无进展生存期（PFS），而常规化疗为 2.8 个月，提示为经过标准治疗后病情进展的患者提供了潜在的新治疗选择。在肝癌领域，由复旦大学附属中山医院的贾凡院士和慈溪市先进研究所的秦树奎教授共同领导的 CARES-336 研究首次证明，“卡瑞利珠单抗 + 阿帕替尼” 方案联合经动脉化疗栓塞（TACE）显著延长了中位 PFS（根据 BIRC 的 mRECIST，11.1 个月对比 8.3 个月），支持该联合方案在不可切除肝细胞癌（uHCC）患者中的潜在应用。</p>
</div><p><strong>Urological Cancers: Dual Breakthroughs in Prostate and Bladder Cancers</strong></p>
<div class="lb-trans"><p><strong>泌尿系统癌症：前列腺癌和膀胱癌的双重突破</strong></p>
</div><p>The FUZUPRO study, led by Professor Dingwei Ye of Fudan University Shanghai Cancer Center, demonstrated that first-line treatment with fluzoparib combined with abiraterone acetate and prednisone for metastatic castration-resistant prostate cancer (mCRPC) resulted in a median radiographic PFS of 24.8 months, compared to 19.9 months with the standard regimen. Another study demonstrated that the anti-Nectin-4 ADC SHR-A2102 combined with adebrelimab achieved a pCR of 48.1% and a pathological downstaging rate of 59.3% in the perioperative treatment of muscle-invasive bladder cancer, including those with renal dysfunction.</p>
<div class="lb-trans"><p>由复旦大学上海癌症中心的叶丁伟教授领导的 FUZUPRO 研究表明，针对转移性去势抵抗性前列腺癌（mCRPC）的首选治疗中，氟唑帕利联合阿比特龙和泼尼松的治疗中位放射学 PFS 为 24.8 个月，而标准方案为 19.9 个月。另一项研究表明，抗 Nectin-4 抗体药物偶联物 SHR-A2102 联合阿德贝利单抗在肌肉侵袭性膀胱癌的围手术期治疗中，获得了 48.1% 的 pCR 和 59.3% 的病理降期率，包括肾功能不全患者。</p>
</div><p><strong>Supportive Cancer Care: Additional Evidence for New Antiemetic Drug</strong></p>
<div class="lb-trans"><p><strong>支持性癌症护理：新抗恶心药物的额外证据</strong></p>
</div><p>The Phase III PROTECT study, led by Professor Li Zhang and Professor Yuhong Li of the Sun Yat-sen University Cancer Center, demonstrated that Fosrolapitant and Palonosetron Hydrochloride for Injection—a novel, ultra-long-acting antiemetic developed in-house by Hengrui—achieved significantly higher complete response rates than the standard regimen during the acute, delayed, and overall phases for the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy. These findings add to the growing body of clinical evidence supporting its use in supportive cancer care.</p>
<div class="lb-trans"><p>由中山大学肿瘤中心的张莉教授和李玉红教授领导的 III 期 PROTECT 研究表明，恒瑞自主研发的新型超长效抗恶心药物 Fosrolapitant 和盐酸帕洛诺司琼注射液在预防中度致吐化疗引起的恶心和呕吐的急性、延迟和整体阶段中，获得了显著高于标准方案的完全应答率。这些发现为其在支持性癌症护理中的应用提供了越来越多的临床证据。</p>
</div><p><strong>Hengrui Pharma</strong> currently markets 16 approved oncology medicines in China and is advancing nearly 60 oncology candidates across its research portfolio. The company is conducting more than 150 clinical trials worldwide across its key oncology development programs.</p>
<div class="lb-trans"><p><strong>恒瑞医药</strong> 目前在中国市场上销售 16 种已批准的肿瘤药物，并在其研究组合中推进近 60 个肿瘤候选药物。公司在全球范围内开展超过 150 项临床试验，涵盖其关键的肿瘤开发项目。</p>
</div><p>Hengrui's expanding presence at the ASCO Annual Meeting reflects continued progress across its oncology pipeline and broader clinical development efforts. The company's research presentations this year span multiple tumor types and therapeutic modalities, highlighting both approved medicines and investigational candidates across its oncology portfolio.</p>
<div class="lb-trans"><p>恒瑞在 ASCO 年会上的不断扩展反映了其肿瘤管线和更广泛的临床开发工作的持续进展。今年公司的研究报告涵盖多种肿瘤类型和治疗方式，突显了其肿瘤产品组合中的已批准药物和研究候选药物。</p>
</div><p>As oncology research continues to evolve globally, Hengrui remains focused on translating scientific innovation into potential clinical benefit for patients through sustained investment in research and development.</p>
<div class="lb-trans"><p>随着全球肿瘤研究的不断发展，恒瑞医药始终专注于通过持续的研发投资，将科学创新转化为患者潜在的临床益处。</p>
</div><p>SOURCE Hengrui Pharma</p>
<div class="lb-trans"><p>来源：恒瑞医药</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNjAxJk5ld3NJdGVtSWQ9Q043MjIyNCZUcmFuc21pc3Npb25fSWQ9MjAyNjA2MDEwMTUxUFJfTkVXU19VU1BSX19fX19DTjcyMjI0" alt="" original-src="https://rt.prnewswire.com/rt.gif?NewsItemId=CN72224&amp;Transmission_Id=202606010151PR_NEWS_USPR_____CN72224&amp;DateId=20260601"/></p>

恒瑞医药在 2026 年 ASCO 会议上展示了超过 90 项肿瘤学研究，突显了在多种肿瘤类型上的进展